Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.

Chemistry has been developed to access both imidazo[1,2-a]pyrazines and imidazo[1,2-c]pyrimidines. Small structural modifications in both series led to a switch of potency between two kinases involved in mediating cell cycle checkpoint control, CHK1 and MK2.

[1]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[2]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[3]  Michael B Yaffe,et al.  MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. , 2005, Molecular cell.

[4]  S. Carr,et al.  DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. , 2010, Molecular cell.

[5]  M. Yaffe,et al.  Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. , 2009, Current opinion in cell biology.

[6]  Yun Dai,et al.  New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network , 2010, Clinical Cancer Research.

[7]  I. Collins,et al.  Checkpoint kinase inhibitors: a patent review (2009 – 2010) , 2011, Expert opinion on therapeutic patents.

[8]  K Nasmyth,et al.  Viewpoint: Putting the Cell Cycle in Order , 1996, Science.

[9]  W. Seghezzi,et al.  Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening , 2011, Molecular Cancer Therapeutics.

[10]  M. Gaestel,et al.  MAPKAP kinases — MKs — two's company, three's a crowd , 2006, Nature Reviews Molecular Cell Biology.

[11]  P. O'Connor,et al.  Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 , 2008, Molecular Cancer Therapeutics.

[12]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[13]  E. Appella,et al.  Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase , 2001, Nature.

[14]  A. Sancar,et al.  Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. , 2004, Annual review of biochemistry.

[15]  Stephen Green,et al.  AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies , 2008, Molecular Cancer Therapeutics.

[16]  W. Brownell,et al.  Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems. , 2000, Genes & development.

[17]  Michael B Yaffe,et al.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.

[18]  S. Elledge,et al.  The DNA damage response: putting checkpoints in perspective , 2000, Nature.

[19]  D. Toczyski,et al.  A unified view of the DNA-damage checkpoint. , 2002, Current opinion in cell biology.